// App-Quantinova.ai

Sa1961 : ONE YEAR OF DUODENAL-JEJUNAL BYPASS LINER THERAPY (ENDOBARRIER®) LEADS TO SIGNIFICANT CHANGES IN LIVER BIOCHEMISTRY ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Researchers

Presenter

  • Aruchuna Ruban

Principal Investigators

  • Michael Glaysher

  • Alexander Miras

  • Christina G. Prechtl

  • Anthony P. Goldstone

  • Nicholas A. Johnson

  • Madhawi Aldhwayan

  • Navpreet Chhina

  • Werd Al-Najim

  • Hutan Ashrafian

  • Mayank Patel

  • James Byrne

  • Julian P. Teare

Medical Centers

  • University College Dublin, Dublin 4, Ireland

  • King Saud University, Riyadh, Saudi Arabia

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

  • University of Southampton, Southampten, United Kingdom

Locations

  • Ireland

  • Saudi Arabia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Nonalcoholic fatty liver disease

  • Type 2 diabetes mellitus

Biomarkers

  • Aspartate aminotransferase

  • Alkaline phosphatase

  • Alanine transaminase

  • Gamma glutamyltransferase

  • Body mass index

Drug/Treatment

  • Alkaline phosphatase

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Controlled

Phase

  • NA

Study Id's

  • NCT02459561

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved